Close
Patheon

Patheon Achieved More Outsourced New Drug Approvals Than Any Other Provider According to 2017 PharmSource CMO Scorecard

Company “dominated” latest industry report with approximately 30 percent of all outsourced approvals, four times more than the nearest competitor

Category:

Thursday, March 30, 2017 6:30 am EDT

Dateline:

DURHAM, N.C.

Public Company Information:

NYSE:
PTHN
NL0011970280

We’re the only CMO recognized for NDA approvals in drug substance and drug product. (Source: @pharmsource)

DURHAM, N.C.--(BUSINESS WIRE)--Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical sector, has been cited once again as capturing the most outsourced new drug approvals (NDAs) in the US than any other contract manufacturing organization (CMO) in 2016. NDAs are authorized by the U.S. Food and Drug Administration (FDA).

The annual 2017 PharmSource CMO Scorecard underscores the company’s leadership position in the CMO sector highlighting the fact that Patheon is supporting approximately 30 percent of all new drug approvals on behalf of clients in 2016 and has been awarded approximately 25 percent of all outsourced approvals in the last decade (2007-2016).

“Patheon continues to bring expertise, value and a solid track record in navigating the regulatory needs of clients, resulting in the company gaining a dominant share of product approvals in 2016 and over the last 10 years,” said Michael Lehmann, president, global sales and marketing. “Securing market approval is key to pharma companies’ success and Patheon has the experience navigating the path to a regulatory approval.”

Key findings of the report include Patheon receiving:

  • 17 out of 55 (30 percent) of all outsourced NDA approvals in 2016, four times more than the closest competitor
  • 112 new molecular entity (NME) and non-NME NDA approvals, as many as the next six leading CMOs combined (2007-2016)
  • Significant awards for solid dose NME approvals, solid dose non-NME approvals and parenteral NME approvals in the last ten years.

Patheon was the only CMO recognized for having multiple approvals for both drug substance and drug product.

The annual PharmSource CMO Scorecard analyzes the CMO industry, using NDA approvals as a key indicator of performance, with data compiled from a broad array of public sources including regulatory and financial filings, and press releases. PharmSource, A GlobalData company, is an independent provider of market intelligence on the contract manufacturing industry.

About Patheon

Patheon is a leading global provider of pharmaceutical development and manufacturing services. With approximately 9,100 employees and contractors worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help clients of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. A Healthier World. Delivered.

Contact:

Patheon N.V.
Mari Mansfield, +1-919-226-3137
Senior Director, External Communications
Mari.Mansfield@Patheon.com
media@patheon.com

Media Contact

Mari Mansfield
4815 Emperor Blvd.,
Durham, NC 27703
(919) 226-3137
mari.mansfield@patheon.com

 
 

Media Contact

Mari Mansfield
4815 Emperor Blvd.,
Durham, NC 27703
(919) 226-3137
mari.mansfield@patheon.com